Chromocell Therapeutics (Chromocell Therapeutics) Short-Term Debt : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Chromocell Therapeutics Short-Term Debt?

Chromocell Therapeutics's Short-Term Debt for the quarter that ended in Mar. 2024 was $0.00 Mil.

Chromocell Therapeutics's quarterly Short-Term Debt increased from Sep. 2023 ($1.20 Mil) to Dec. 2023 ($1.27 Mil) but then declined from Dec. 2023 ($1.27 Mil) to Mar. 2024 ($0.00 Mil).

Chromocell Therapeutics's annual Short-Term Debt increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.54 Mil) and increased from Dec. 2022 ($0.54 Mil) to Dec. 2023 ($1.27 Mil).

Chromocell Therapeutics Short-Term Debt Historical Data

The historical data trend for Chromocell Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chromocell Therapeutics Short-Term Debt Chart

Chromocell Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

0.24

0.54

1.27

Chromocell Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial							0.74	0.98	1.20	1.27	-

Chromocell Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Chromocell Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Chromocell Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Chromocell Therapeutics (Chromocell Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chromocell Therapeutics Corp (AMEX:CHRO) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Chromocell Therapeutics Corp is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as "NaV1.7", as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology.